Navigation Links
Montclair Breast Center Introduces Online Breast Cancer Risk Quiz
Date:7/25/2013

Montclair, NJ (PRWEB) July 25, 2013

In June of 2013, actress Angelina Jolie announced that a genetic screening test revealed she carried a BRCA 1 genetic mutation that elevated her chances of developing breast or ovarian cancer. Her decision to undergo a double mastectomy created a storm of awareness and controversy about genetic testing and surgical procedures for breast cancer prevention.

Angelina Jolie’s condition is known as hereditary breast and ovarian cancer syndrome and accounts for 5–10% of all breast cancer cases. But according to Montclair Breast Center Founder and Director, Dr. Nancy Elliott, there is much more to being aware and vigilant about breast health than this one issue of genetic testing. She says, “Genetic testing is critical for some women, but genetic mutations account for cancers in a very small population of women overall, so it is critical to become savvy about all risk factors for breast cancer. Women need to know their family medical history of cancers and other disease, understand how diet, weight and exercise can impact their risk factors and certainly learn more about genetic testing if it is indicated to be of value for them.”

To increase awareness of breast health and risk factors for breast cancer, Dr. Elliott has introduced a free Montclair Breast Center Risk Quiz, available online at http://www.montclairbreastcenter.com. Surprisingly, the risk quiz consists of just eight short questions and an easy point system for estimating risk for breast cancer from 0–10 (average risk), 11–19 (moderate risk), 20 & Over (high risk) to Over 30 (highest risk). While not represented as a scientific result, Dr. Elliott suggests that this easy and quick quiz is a practical first step in hel
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Montclair Breast Center introduces 3D Mammography.
2. Signal Genetics Announces Publication of BreastPRS™ Validation Study with Weill Cornell Medical College, New York
3. Research Shows That SurePure Technology Offers Alternative to Thermal Pasteurization of Human Breast Milk
4. CTI Reports Final Results from Cooperative Group and NCI-Sponsored Trial of Brostallicin in Patients with Metastatic Triple-Negative Breast Cancer
5. Novartis highlights new findings in advancing care for patients with 170 abstracts in breast, lung and blood cancers at ASCO and EHA
6. MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer
7. Agendia Reports More Than 20,000 MammaPrint Breast Cancer Recurrence Results
8. Stereotactic Breast Biopsy introduced with Fischer-Giotto Image at American Society of Breast Surgeons course
9. Robert Lowen MD, Expert Bay Area Plastic Surgeon, Announces Cutting-Edge 3-D Crisalix Imaging Technology to Aid Patients in Choosing their Breast Implant Size
10. Patti Flint MD, A Top Female Plastic Surgeon in the Southwest, Is Proud To Offer Cutting-Edge 3D Crisalix Technology to Patients When Selecting Breast Implants
11. Dr. Vasquez at the Connecticut Plastic Surgery Group Now Offers the Unique Crisalix 3D Simulations for Facial Aesthetics and Breast Augmentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... August 3, 2015 E-QURE Corp. ... of its Bio-electrical Signal Therapy device ("BST Device"), a ... hard to heal chronic wounds, today announced that the ... an Israeli distributor specializing in medical devices, for the ... Chemipal is a 70 years old, sales, marketing and ...
(Date:8/3/2015)... Aug. 3, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (TSX.V: ... on the development of autologous cell therapies, announced today that ... the InvestMNT conference held in Minneapolis, Minnesota ... time. Hall,s presentation will highlight RepliCel,s 18-month milestones including CE ... Europe , clinical data from both RCT-01 (tendon) ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... competitive market analysis and premium industry insights on the global resorcinol industry. The ... a collective study of vivid market scenarios and analysis of primary and secondary ...
(Date:7/30/2015)... ... , ... Ralco is honored to announce that it is the primary sponsor ... August 5-9 in Marshall. The Ralco Enrichment Center is an interactive experience where the ... their daily lives. This unique exhibit also features a birthing center for fair goers ...
Breaking Biology Technology:E-QURE Corp Signs Second Distribution Agreement in Israel 2E-QURE Corp Signs Second Distribution Agreement in Israel 3RepliCel Presenting at InvestMNT Investor Conference in Minneapolis 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2
... NEEDHAM, Mass., Jan. 22 Hospitals and ... procedures that allow,construction projects to take place ... free white paper that addresses these challenges ... The white paper, titled "Infection Control ...
... Barr Pharmaceuticals,Inc. (NYSE: BRL ) today ... with,Ortho Women,s Health & Urology, Division of ... settle the,outstanding patent litigation involving Ortho Women,s ... LO (norgestimate/ethinyl,estradiol). The United States District Court ...
... Speed in Reaching First Clinical Milestone Validates Approach, ... today,announced the successful completion of its first clinical ... for SYN-111,(rufinamide), a sodium channel blocker. Rufinamide was ... by Eisai in Europe as a,drug to treat ...
Cached Biology Technology:White Paper Details Infection Control Challenges Hospitals Must Address During Construction 2Barr and Ortho Women's Health & Urology in Discussions to Settle ORTHO TRI-CYCLEN(R) LO Patent Litigation 2Barr and Ortho Women's Health & Urology in Discussions to Settle ORTHO TRI-CYCLEN(R) LO Patent Litigation 3Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders 2Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders 3
(Date:7/8/2015)... SAN DIEGO , July 8, 2015 /PRNewswire/ ... of cell-free molecular diagnostics, today announced the launch ... of the Company,s Precision Cancer Monitoring℠ (PCM) technology ... patients receiving one or a combination of the ... and Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient ...
(Date:7/7/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company") ... announces a revised version of one of its first 30 second ... CNBC in New York , Chicago ... San Francisco metro areas.    , , ... replace all the cards in your wallet and keep your identity ...
(Date:6/30/2015)... 30, 2015 To bolster its efforts and commitment ... announced today the addition of two new team members. ... advisor and David Raviv will act as head ... Corp.,s commitment to providing the most secure solutions for the ... co-founded Layer 7 Technologies, a provider of security and management ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3
... altered osteoporosis drug may be useful in fighting malaria, researchers ... other parasitic protozoa, the drug readily crosses into the red ... The drug works at very low concentrations with no observed ... Proceedings of the National Academy of Sciences . ...
... A group of scientists from across the world have come ... into how fructose causes obesity and metabolic syndrome, more commonly ... performed in lab animals, researchers found that fructose can be ... One form appears to be responsible for causing how fructose ...
... CA--A study of the tropical coral reef system along the ... could threaten the long-term health of the reefs. Led by ... was published in the journal Coral Reefs (online ... loss of predatory fish leads to a cascade of effects ...
Cached Biology News:Modified bone drug kills malaria parasite in mice 2Research offers insight to how fructose causes obesity and other illness 2Coral reef study traces indirect effects of overfishing 2
Rabbit polyclonal to Kallikrein 1 ( Abpromise for all tested applications). Antigen: Full length native kallikrein from tissue (Human) Entrez Gene ID: 3816 Swiss Protein ID: P06870...
Biotin d anti-mouse Tim-1...
... Kir2.1 protein. The epitope is specific ... in any other known protein.,SPECIES REACTIVITIES: ... in rabbit, bovine, porcine and guinea ... rat and mouse (17/19 residues) and ...
Mouse monoclonal [J53] to Thyroid Hormone Receptor beta 1 ( Abpromise for all tested applications). entrezGeneID: 7068 SwissProtID: P10828...
Biology Products: